Is uric acid removed during hemodialysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, uric acid is effectively removed during hemodialysis

Hemodialysis removes uric acid efficiently, with typical reductions of 64-66% per session, though pre-dialysis levels often remain elevated above normal values. 1, 2

Mechanism and Efficiency of Uric Acid Removal

Uric acid behaves as a small, water-soluble, non-protein-bound molecule that is readily cleared during hemodialysis through diffusion across the dialyzer membrane. The removal characteristics are similar to other small solutes like urea and creatinine 3.

Key Evidence on Removal Rates:

  • Single HD session: Uric acid concentrations decrease by approximately 64.6% (from mean 44.16 to 15.61 μmol/L) 1
  • Mean clearance: Approximately 66% ± 10% with standard twice-weekly dialysis 2
  • Pre-dialysis levels typically remain 81.9% above normal despite regular dialysis 2

Clinical Implications

Factors Affecting Uric Acid Clearance:

The efficacy of uric acid removal is significantly influenced by:

  • Kt/V adequacy: Kt/V < 1.2 substantially reduces clearance efficiency (OR 0.1) 2
  • Body weight: Excess weight decreases removal efficiency (OR 0.4) 2
  • Dialysis frequency: Daily hemodialysis (6 sessions/week) achieves lower pre-dialysis uric acid levels (9.14 to 8.16 mg/dL) compared to standard thrice-weekly schedules 3

Important Caveats:

While uric acid is removed during dialysis, post-dialysis levels may still exceed normal ranges 1. This occurs because:

  1. Rapid reaccumulation between sessions
  2. Continued production from purine metabolism
  3. Inadequate total weekly clearance with standard dialysis schedules

Practical Monitoring Considerations

Uric acid has unique utility in dialysis monitoring. Uric acid is the major determinant of UV absorbance in spent dialysate, allowing spectrophotometric evaluation of dialysis dose 4. The removal kinetics of uric acid parallel urea removal closely enough that dialysate absorbance measurements can serve as a surrogate marker for dialysis efficiency 4.

Special Clinical Scenario:

In acute anuric uric acid nephropathy, hemodialysis with high uric acid clearance is the most efficient treatment, superior to other therapeutic modalities for managing both the uremic state and intrarenal crystal obstruction 5.

Optimization Strategies

To maximize uric acid control in dialysis patients:

  • Ensure Kt/V > 1.2 at minimum 2
  • Consider more frequent dialysis schedules (daily or nocturnal) for better control 3
  • Combine hemodialysis with uric acid-lowering drugs and dietary modifications rather than relying on dialysis alone 2
  • Monitor adequacy monthly as recommended by KDOQI guidelines 6

The KDOQI guidelines emphasize that while urea serves as the primary marker for dialysis adequacy 6, the removal of other small solutes like uric acid follows similar kinetics and benefits from adequate dialysis dosing.

Related Questions

A woman with serum uric acid of 6.4 mg/dL presents with foot pain; what is the recommended management?
What is the clinical significance of a serum uric acid level of 6.6 mg/dL and what management steps are recommended?
What is the optimal serum uric acid level to target in patients with gout or uric‑stone disease versus those without these conditions?
How should elevated serum uric acid be interpreted in an adult patient?
Does a plain radiograph (X‑ray) show uric acid crystals?
In a morbidly obese patient with total bilirubin 8 mg/dL, mild AST/ALT elevation (~58 U/L), alkaline phosphatase 107 U/L, jaundice, epigastric tenderness, CT (computed tomography) showing gallstones with pericholecystic fluid, and ongoing MSSA (methicillin‑susceptible Staphylococcus aureus) bacteremia on cefazolin, what does a direct (conjugated) bilirubin level of 5.3 mg/dL indicate and what is the appropriate next diagnostic and therapeutic step?
What strategies can be employed to prevent or mitigate weight gain associated with gabapentin therapy?
What is the incidence of cerebral insult (stroke or ischemic brain event) associated with surgical atrial septal defect (ASD) closure?
What are the adverse effects of topiramate?
What is the recommended immediate oral management for a patient with hypertensive urgency (blood pressure ≥180/120 mm Hg) without acute target‑organ damage?
What is the appropriate treatment for an 85‑year‑old patient with community‑acquired pneumonia, including empiric antibiotic choices, dosing adjustments for impaired renal function, and considerations for inpatient versus outpatient management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.